New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary

INDIANAPOLIS , Sept. 27, 2021 /PRNewswire/ -- New data from Eli Lilly and Company's (NYSE: LLY) monarchE study for an investigational use of Verzenio ® (abemaciclib), in combination with endocrine therapy, in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor